---
title: "Harbin Medisan Pharmaceutical Co., Ltd . (002900.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002900.SZ.md"
symbol: "002900.SZ"
name: "Harbin Medisan Pharmaceutical Co., Ltd ."
industry: "Pharmaceuticals"
datetime: "2026-05-20T23:47:58.827Z"
locales:
  - [en](https://longbridge.com/en/quote/002900.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002900.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002900.SZ.md)
---

# Harbin Medisan Pharmaceutical Co., Ltd . (002900.SZ)

## Company Overview

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate mesylate for injection, bismuth potassium citrate granules, pantoprazole sodium for injection, ambroxol hydrochloride and glucose injection, asarone for injection, paracetamol and tramadol hydrochloride tablets, rifamycin sodium for injection, lornoxicam for injection, vecuronium bromide for injection, and vitamin c for injection. It also provides medical devices and cosmetics.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.medisan.com.cn](https://www.medisan.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: D (0.72)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 198 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -25.44% |  |
| Net Profit YoY | -2978.80% |  |
| P/B Ratio | 2.02 |  |
| Dividend Ratio | 1.77% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3577995770.37 |  |
| Revenue | 814676625.91 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -16.31% | E |
| Profit Margin | -39.08% | E |
| Gross Margin | 40.88% | B |
| Revenue YoY | -25.44% | E |
| Net Profit YoY | -2978.80% | E |
| Total Assets YoY | -10.67% | E |
| Net Assets YoY | -17.24% | E |
| Cash Flow Margin | 33.46% | D |
| OCF YoY | -25.44% | E |
| Turnover | 0.23 | D |
| Gearing Ratio | 46.93% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Harbin Medisan Pharmaceutical Co., Ltd .",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-25.44%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-2978.80%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.02",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.77%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3577995770.37",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "814676625.91",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-16.31%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-39.08%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "40.88%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-25.44%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-2978.80%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.67%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-17.24%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "33.46%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-25.44%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.23",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "46.93%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.15 | 176/215 | 459.61 | 439.27 | 422.65 |
| PB | 2.01 | 84/215 | 2.31 | 2.15 | 2.01 |
| PS (TTM) | 4.36 | 116/215 | 4.74 | 4.44 | 4.22 |
| Dividend Yield | 1.79% | 75/215 | 1.68% | 1.52% | 1.35% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002900.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002900.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002900.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002900.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**